down arrow

Zomedica Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA98980M1095
USD
0.11
0 (-1.8%)

Dec 22

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.090.11

52 Week

0.020.16
Valuation
Technical
Day's Volume

CASH

3.78 M

Shareholding (Mar 2025)

FII

0.86%

Held by 12 FIIs

DII

92.66%

Held by 17 DIIs

Promoter

0.00%

How big is Zomedica Corp.?

22-Jun-2025

As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, with net sales of 27.53 million and a net profit of -101.63 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.

Market Cap: As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Zomedica Corp. reported net sales of 27.53 million and a net profit of -101.63 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.

Read More

What does Zomedica Corp. do?

22-Jun-2025

Zomedica Corp. is a veterinary diagnostic and pharmaceutical company focused on companion animals, with recent quarterly net sales of $7 million and a net loss of $64 million. The company has a market cap of $41.65 million and no dividend yield.

Overview: <BR>Zomedica Corp. is a development stage veterinary diagnostic and pharmaceutical company focused on developing products for companion animals within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -64 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 41.65 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.48 <BR>Return on Equity: -22.48% <BR>Price to Book: 0.31 <BR><BR>Contact Details: <BR>Address: 100 Phoenix Drive, Suite 180, ANN ARBOR MI: 48108 <BR>Tel: 1 734 3692555 <BR>Website: http://www.zomedica.com/

Read More

Who are in the management team of Zomedica Corp.?

22-Jun-2025

As of March 2022, Zomedica Corp.'s management team includes Chairman Jeffrey Rowe, CEO Robert Cohen, Chief Medical Officer Dr. William MacArthur, and several independent directors, including Dr. Jane Eagleson and Dr. Johnny Powers, among others. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Zomedica Corp. includes the following individuals:<BR><BR>- Mr. Jeffrey Rowe, Chairman of the Board<BR>- Mr. Robert Cohen, Chief Executive Officer and Director<BR>- Dr. William MacArthur, Executive Member and Chief Medical Officer, Director of Research and Development<BR>- Mr. Christopher Wolfenberg, Director<BR>- Dr. Jane Eagleson, Independent Director<BR>- Christopher MacLeod, Independent Director<BR>- Dr. Johnny Powers, Independent Director<BR>- Mr. Thomas Robitaille, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Zomedica Corp. overvalued or undervalued?

20-Sep-2025

As of March 1, 2022, Zomedica Corp. is rated as "risky" and appears overvalued with key metrics indicating a lack of profitability, including a Price to Book Value of 0.33 and a P/E ratio of -2.71, suggesting significant risk compared to its peers.

As of 1 March 2022, Zomedica Corp. has moved from a "does not qualify" rating to "risky." The company appears to be overvalued given its current metrics. Key valuation ratios include a Price to Book Value of 0.33, an EV to EBIT of 0.58, and an EV to EBITDA of 0.77, all indicating a lack of profitability and financial stability. <BR><BR>In comparison to its peers, Zomedica's P/E ratio is -2.71, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Gossamer Bio, Inc. has a P/E of -4.38, suggesting that Zomedica is not the worst performer in its group but still reflects significant risk. The recent stock performance comparison with the S&P 500 is not available, yet the overall valuation metrics reinforce the notion of Zomedica being overvalued in its current state.

Read More

Is Zomedica Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Zomedica Corp.'s technical trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, while underperforming the S&P 500 with a 1-week return of -26.68% and a 1-year return of -34.04%.

As of 12 September 2025, the technical trend for Zomedica Corp. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD and KST are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the Bollinger Bands reflect a mildly bullish stance weekly but a mildly bearish one monthly. <BR><BR>In terms of performance, Zomedica has underperformed the S&P 500 across multiple periods, with a 1-week return of -26.68% compared to the S&P's 1.05%, and a 1-year return of -34.04% versus the S&P's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 79 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.46

stock-summary
Return on Equity

-23.35%

stock-summary
Price to Book

0.63

Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.91%
0%
33.91%
6 Months
165.85%
0%
165.85%
1 Year
-9.17%
0%
-9.17%
2 Years
-50.48%
0%
-50.48%
3 Years
-34.77%
0%
-34.77%
4 Years
-69.72%
0%
-69.72%
5 Years
-47.27%
0%
-47.27%

Zomedica Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
96.59%
EBIT Growth (5y)
-184.27%
EBIT to Interest (avg)
-27.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.13
Tax Ratio
0.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.33
EV to EBIT
0.58
EV to EBITDA
0.77
EV to Capital Employed
-0.28
EV to Sales
-0.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-22.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (6.48%)

Foreign Institutions

Held by 12 Foreign Institutions (0.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.75% vs 1.67% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 69.04% vs -359.62% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.00",
          "val2": "6.10",
          "chgp": "14.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.10",
          "val2": "-7.10",
          "chgp": "14.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-16.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-23.90",
          "chgp": "69.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,153.80%",
          "val2": "-1,475.00%",
          "chgp": "32.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.33% vs 33.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -36.23% vs -102.94% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.30",
          "val2": "25.20",
          "chgp": "8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.00",
          "val2": "-25.30",
          "chgp": "-6.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.00",
          "val2": "-11.70",
          "chgp": "-36.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-34.50",
          "chgp": "-36.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,283.80%",
          "val2": "-1,254.30%",
          "chgp": "-2.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
7.00
6.10
14.75%
Operating Profit (PBDIT) excl Other Income
-6.10
-7.10
14.08%
Interest
0.00
0.00
Exceptional Items
0.00
-16.00
100.00%
Consolidate Net Profit
-7.40
-23.90
69.04%
Operating Profit Margin (Excl OI)
-1,153.80%
-1,475.00%
32.12%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 14.75% vs 1.67% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 69.04% vs -359.62% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
27.30
25.20
8.33%
Operating Profit (PBDIT) excl Other Income
-27.00
-25.30
-6.72%
Interest
0.00
0.20
-100.00%
Exceptional Items
-16.00
-11.70
-36.75%
Consolidate Net Profit
-47.00
-34.50
-36.23%
Operating Profit Margin (Excl OI)
-1,283.80%
-1,254.30%
-2.95%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.33% vs 33.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -36.23% vs -102.94% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Zomedica Corp. stock-summary
stock-summary
Zomedica Corp.
Pharmaceuticals & Biotechnology
Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.
Company Coordinates stock-summary
Company Details
100 Phoenix Drive, Suite 180 , ANN ARBOR MI : 48108
stock-summary
Tel: 1 734 3692555
stock-summary
http://www.zomedica.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."